TRU-SENTIMENT · DeltaNeutral
XNCR Trading Analysis - 10/20/2026 04:17 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
XNCR (Xencor Inc.) at $24.73. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $1,880 vs put $0. RSI 38.5.
- Symbol
- XNCR
- Price
- $24.73
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-10-20 16:17:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options):From TRUE SENTIMENT OPTIONS data (2026-10-20):
Call Volume: $1,880.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $1,880.00
- Sentiment: Bullish (call_pct 100.0, put_pct 0.0).
- Directional conviction: 4 call contracts, 0 put, 1 call trade — pure bullish bet via delta 40-60 filter.
- Near-term expectation: Options flow implies upside anticipation despite weak technicals.
- Divergence: Technicals bearish (RSI 38.52, MACD neg) vs sentiment bullish — spread recommendation flags "divergence detected".
Key Statistics: XNCR
Fundamental Snapshot
Valuation
| P/E (trailing) | 59.50 |
| EPS (trailing 12 mo) | $-2.16 |
| Market cap | $1.84B |
| Shares outstanding | 74.4M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.17 |
| 52-week low | $10.38 |
| 52-week high | $30.61 |
| Historical volatility | 45.9% |
Ownership & trading
| Institutional ownership | 59.7% |
| Average daily volume | 1.4M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context:
Xencor (XNCR) is a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies for cancer and autoimmune diseases. Based on general knowledge, recent context likely includes:
- Pipeline updates from ongoing Phase 1/2 trials in immuno-oncology, with potential interim data readouts expected in late 2026.
- Positive preclinical data presented at major medical conferences (e.g., ASH or ASCO) supporting XmAb platform advancements.
- Potential partnership or licensing news with larger pharma players seeking bispecific antibody expertise.
- No confirmed earnings date in provided data, but historical fiscal year end is 2025-12-01, suggesting next annual reporting in early 2026.
- Context: Headlines of pipeline progress may contrast with weak technicals (RSI 38.52, price below SMAs), while options sentiment shows bullish conviction — possible anticipation of catalysts not yet reflected in price.
Fundamental Analysis:
Based strictly on embedded FUNDAMENTALS data for XNCR:
- Trailing P/E: 59.50; Trailing EPS: -2.16 (negative earnings, typical for clinical-stage biotech).
- Market Cap: $1,838,749,690; Shares Outstanding: 74,353,000; Institutional Ownership: 59.71%.
- Dividend Yield: 0.00%; No dividend declared (ex-dividend date null).
- Beta: 1.17 (moderate volatility vs market); 52-Week High: $30.61; 52-Week Low: $10.38.
- Average Volume: 1,369,000; Historical Volatility: 45.86%.
- Revenue growth, gross/operating/net margins, ROE, Debt/Equity, Free Cash Flow, PEG, forward PE/EPS, price-to-book, total revenue, analyst target price: all null in data — not available for comparison.
- Valuation: High trailing P/E of 59.50 with negative EPS indicates market prices in future pipeline success, not current profitability. No PEG to assess growth-adjusted value.
- Fundamentals diverge from technicals: negative EPS and high beta coincide with weak price trend (below SMAs) but options sentiment is bullish.
Current Market Position:
From minute bars (2026-10-19 to 2026-10-20) and daily history:
- Daily close on 2026-10-19: $23.01; Intraday last bar 2026-10-20 15:50: close $24.73 (up from 09:45 open $22.99 two-day span).
- Recent daily action: 2026-10-16 close $22.93, 2026-10-19 low $21.97 (30-day low), rebound to $23.01.
- Minute bars show recovery: 2026-10-19 09:45 low $22.27, by 2026-10-20 15:35 high $25.00, close $24.73.
- Intraday momentum: Rising from $22.37 (10-19 09:45) to $24.73 (10-20 15:50), volume spike 10-19 at 1,308,714.
Technical Analysis:
Technical Indicators
- SMA alignment: Price $23.01 < SMA5 $23.42 < SMA20 $24.36 < SMA50 $25.07 — bearish stack, no golden cross.
- RSI 38.52: Weak momentum, approaching oversold (<30) but not yet.
- MACD -0.30 below signal -0.24, histogram -0.06: Bearish momentum persisting.
- Bollinger: Price $23.01 between lower $22.85 and mid $24.36 — near lower band, no squeeze (width $3.01).
- 30-day range: Price at $23.01 is 13% above low $21.97, 13% below high $26.49.
True Sentiment Analysis (Delta 40-60 Options):
From TRUE SENTIMENT OPTIONS data (2026-10-20):
Call Volume: $1,880.00 (100.00%) Put Volume: $0.00 (0.00%) Total: $1,880.00
- Sentiment: Bullish (call_pct 100.0, put_pct 0.0).
- Directional conviction: 4 call contracts, 0 put, 1 call trade — pure bullish bet via delta 40-60 filter.
- Near-term expectation: Options flow implies upside anticipation despite weak technicals.
- Divergence: Technicals bearish (RSI 38.52, MACD neg) vs sentiment bullish — spread recommendation flags "divergence detected".
Key Price Levels (observational only):
Interactive charts load with JavaScript. This text is the crawlable summary.